Validating a nonhuman primate model of super-selective intraophthalmic artery chemotherapy: Comparing ophthalmic artery diameters

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 12, 2012, Pages 7791-7794

  Ditta, Lauren C ^a   Choudhri, Asim F ^a,b   Tse, Brian C ^a   Landers, Mark M ^a   Haik, Barrett G ^a,c   Steinle, Jena J ^a   Williams, J Scott ^a   Wilson, Matthew W ^a,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b LE BONHEUR CHILDREN S HOSPITAL   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DIAMETER; CANCER CHEMOTHERAPY; CANNULATION; CHILD; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; INFANT; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMIC ARTERY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETINOBLASTOMA; RHESUS MONKEY; VALIDATION PROCESS; ANIMAL; COMPARATIVE STUDY; EXPERIMENTAL NEOPLASM; INTRAARTERIAL DRUG ADMINISTRATION; MAGNETIC RESONANCE ANGIOGRAPHY; PATHOLOGY; RADIOGRAPHY; REPRODUCIBILITY; RETINA TUMOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENT;

ANIMALS; ANTINEOPLASTIC AGENTS; INJECTIONS, INTRA-ARTERIAL; MACACA MULATTA; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NEOPLASMS, EXPERIMENTAL; OPHTHALMIC ARTERY; REPRODUCIBILITY OF RESULTS; RETINAL NEOPLASMS; RETINOBLASTOMA; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84872174301     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10605     Document Type: Article

References (31)

1. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol. 2004;9:69-73.
2. Abramson DH, Dunkel IJ, Brodie SE, et al. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma. Ophthalmology. 2008;115:1398-1404.
3. Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol. 2011;129:1399-1406.
4. Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH. Intraarterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011;129:732-737.
5. Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications. Arch Ophthalmol. 2011;129:1407-1415.
6. Munier FL, Beck-Popovic M, Balmer A, et al. Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma. Retina. 2011;31:566-573.
7. Peterson EC, Elhammady MS, Quintero Wolfe S, et al. Selective artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors. J Neurosurg. 2001;114:1603-1608.
8. Shields CL, Ramasubramanian S, Shah S, et al. Effect of intraarterial chemotherapy on retinoblastoma-induced retinal detachment. Retina. 2012;32:799-804.
9. Abramson DH, Marr BP, Brodie SE, Dunkel I, Palioura S, Gobin YP. Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five year review. PloS one. 2012; 7;e34120. doi:10.1371/journal.pone.0034120.
10. Abramson DH, Dunkel IJ, Brodie SE, et al. Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology. 2010;117: 1623-1629.
11. Abramson DH, Dunkel IJ, Brodie SE, et al. Bilateral superselective ophthalmic artery chemotherapy for bilateral retinoblastoma: tandem therapy. Arch Ophthalmol. 2010;128:370-372.
12. Shields CL, Kaliki S, Shah SU, et al. Minimal exposure (one or two cycles) of intra-arterial chemotherapy in the management of retinoblastoma. Opthalmology. 2012;119:188-192.
13. Bianciotto C, Shields CL, Iturralde JC, et al. Fluorescein angiographic findings after intra-arterial chemotherapy for retinoblastoma. Ophthalmology. 2012;119:843-849.
14. Marr BP, Gobin PY, Dunkel IJ, et al. Spontaneously resolving periocular erythema and ciliary madarosis following intraarterial chemo- therapy for retinoblastoma. Middle East Afr J Ophthalmol. 2010;17:207-209.
15. Shields CL, Ramasubramanian A, Rosenwasser R. Superselective catheterization of the ophthalmic artery for intraarterial chemotherapy for retinoblastoma. Retina. 2009;29:1207-1209.
16. Shields CL, Shields JA. Intra-arterial chemotherapy for retinoblastoma: the beginning of a long journey. Clin Experiment Ophthalmol. 2010;38:638-643.
17. Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 2010;21:203-212.
18. Vajzovic LM, Murray TG, Aziz-Sultan MA, et al. Supraselective intra-arterial chemotherapy: evaluation of treatment-related complications in advanced retinoblastoma. Clin Ophthalmol. 2011;5:171-176.
19. Wilson MW, Jackson JS, Phillips BX, et al. Real-time ophthalmoscopic findings after superselective intraophthalmic artery chemotherapy in a nonhuman primate model. Arch Ophthalmol. 2011;129:1458-1465.
20. Steinle JJ, Zhang Q, Thompson KE, et al. Intra-ophthalmic artery chemotherapy triggers vascular toxicity through endothelial cell inflammation and leukostasis. Invest Ophthalmol Vis Sci. 2012;53:2439-2445.
21. Wilson MW, Haik BG, Dyer MA. Superselective intraophthalmic artery chemotherapy: what we do not know. Arch Ophthalmol. 2011;129:1490-1491.
22. Berg SL, Aleksic A, McGuffey L, et al. Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates. Cancer Chemother Pharmacol. 2004; 54:127-130.
23. Weinstein JD, Hedges TR. Studies of intracranial and orbital vasculature of the rhesus monkey (Macaca mulatta). Anat Rec. 1962;144:37-41.
24. Berg SL, Stone J, Xiao JJ, et al. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. Cancer Chemother Pharmacol. 2004;54:85-88.
25. Berg S, Serabe B, Aleksic A, et al. Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate. Cancer Chemother Pharmacol. 2001;47:385-390.
26. Vignaud J, Hasso AN, Lasjaunias P, Clay C. Orbital vascular anatomy and embryology. Radiology. 1974;111;617-626.
27. Perrini P, Cardia A, Fraser K, Lanzino G. A microsurgical study of the anatomy and course of the ophthalmic artery and its possibly dangerous anastomoses. J Neurosurg. 2007;106:142-150.
28. Kocabiyik N, Yazar F, Ozan H. The intraorbital course of ophthalmic artery and its relationship with the optic nerve. Neuroanatomy. 2009;8:36-38.
29. Ayajiki K, Tanaka T, Okamura T, Toda N. Evidence for nitroxidergic innervation in monkey ophthalmic arteries in vivo and in vitro. Am J Physiol Heart Circ Physiol. 2000;279; H2006-H2012.
30. Netland PA, Siegner SW, Harris A. Color Doppler ultrasound measurements after topical and retrobulbar epinephrine in primate eyes. Invest Ophthalmol Vis Sci. 1997;38;2655-2661.
31. Levin MH, Gombos DS, O'Brien JM. Intra-arterial chemotherapy for advanced retinoblastoma: is the time right for a prospective clinical trial? Arch Ophthalmol. 2011;129:1487-1489.